Crizotinib, a small-molecule dual inhibitor of c-MET and the ALK receptor tyrosine kinase, has previously demonstrated a significant clinical benefit in patients with EML4-ALK-positive NSCLC in a clinical trial (10,11). The gene discussed is EML4; the disease is non-small cell lung carcinoma.